Clinical trial Recruiting at 1 site Observational Ages 18 and up

Examining retinal blood vessels to understand systemic diseases

Official title: Retinal Microvascularization in OCT-angiography and Systemic Diseases

Run by Centre Hospitalier Universitaire Dijon · NCT06613555 · Data updated 2026-11-12

This study looks at the tiny blood vessels in the eye to see if they can help us understand and predict chronic inflammatory diseases in people with and without systemic vascular conditions.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment5000 (estimated)
SponsorCentre Hospitalier Universitaire Dijon
Academic / other
Locations1 site (Dijon)
StatusRecruiting
StartedJune 19, 2024
Main results expectedJune 2044
Study endsJune 2044
Registry record updatedSeptember 26, 2024
Trial IDNCT06613555 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with systemic vascular pathology, high cardiovascular risk, inflammatory vascular pathology, or preeclampsia, as well as healthy individuals without systemic or vascular issues.

Probably not a fit

Patients with existing ocular diseases or those who do not meet the inclusion criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the relationship between retinal microvascularization and systemic vascular damage. It aims to identify predictive indicators of chronic inflammatory diseases by analyzing the health of small blood vessels in the retina using non-invasive imaging techniques. Patients with systemic vascular conditions and healthy controls will be monitored over time to assess the progression of these diseases. The study utilizes retinal imaging and biological check-ups to gather data.

Why it matters

Potential benefit: If successful, this study could lead to earlier detection and better management of systemic vascular diseases.

How similar studies have gone: While the approach of using retinal microcirculation as a predictive indicator is promising, it is relatively novel and has not been extensively tested in similar studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

For the \"patients with systemic vascular disease\" group

* Patients who have given oral, free and informed consent
* Patients with either :

  * systemic vascular pathology
  * high cardiovascular risk
  * inflammatory vascular pathology
  * preeclampsia during pregnancy

The study will also be offered to patients who have already had an OCT-A examination as part of their routine care, in order to follow them over time.

For the \"healthy control\" group

* Patients who have given free, oral and informed consent
* Patients with no prior systemic or vascular inflammatory pathology, and no high cardiovascular risk
* Non-diabetic patients
* Pregnant patients with risk-free pregnancies recruited from the gynecology department of CHU Dijon Bourgogne OR
* Adult patients without maculopathy recruited from the Ophthalmology Department of CHU Dijon Bourgogne

Exclusion Criteria:

* For the \"patients with systemic vascular disease\" group
* Ophthalmological history in both eyes (vascular and degenerative macular pathologies)
* Protected patient :

  * Minor patient
  * Patient under legal protection (guardianship, curatorship, court order)
  * Patient unable to give consent Person not affiliated to a social security scheme
  * Breast-feeding women
* Person with a contraindication to Tropicamide
* OCT-A signal strength \< 7

For the \"healthy control\" group

* Any pathology studied in the case group
* Ophthalmological history in both eyes (vascular and degenerative macular pathologies)
* Type 1 or type 2 diabetes
* Person with a contraindication to Tropicamide
* Protected person :

  * Minor
  * Person under legal protection (guardianship, curatorship, court order)
  * Person unable to give consent
  * Person not affiliated to a social security scheme
  * Breast-feeding women
* OCT-A signal strength \< 7

Where it's running

  • Chu Dijon Bourogne
    Dijon, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.